SANGAMO THERAPEUTICS, INC 8K

Sangamo Therapeutics, Inc. filed a Chapter 11 Monthly Operating Report showing its cash activity and operating status for the period ended June 30, 2026 in its Delaware bankruptcy case.

Sangamo Therapeutics, Inc., which is in Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10989), filed a Monthly Operating Report for the period ended June 30, 2026, disclosing that the case commenced on June 23, 2026, is being jointly administered, and that during the reporting month the debtor operated with 73 full-time employees, reported beginning cash of $4.9 million, receipts of approximately $10.5 million, disbursements of approximately $1.0 million, and an ending cash balance of about $14.4 million, with required financial schedules and bank documentation attached and the report signed by responsible officer Nikunj Jain on August 6, 2026.

Filing Facts

CIK

1001233

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-346796

Alert Tier

8